来那度胺
骨髓增生异常综合症
医学
内科学
安慰剂
临床研究阶段
贫血
国际预后积分系统
血液肿瘤
肿瘤科
多发性骨髓瘤
临床试验
骨髓
移植
病理
替代医学
作者
Pierre Fenaux,Aristoteles Giagounidis,Dominik Selleslag,Odile Beyne‐Rauzy,Ghulam Mufti,Moshe Mittelman,Petra Muus,Peter A.W. te Boekhorst,Guillermo Sanz,Consuelo del Cañizo,Agnès Guerci‐Bresler,Lars Nilsson,Uwe Platzbecker,Michael Lübbert,Bruno Quesnel,Mario Cazzola,Arnold Ganser,David Bowen,Brigitte Schlegelberger,Carlo Aul
出处
期刊:Blood
[Elsevier BV]
日期:2011-07-14
卷期号:118 (14): 3765-3776
被引量:480
标识
DOI:10.1182/blood-2011-01-330126
摘要
This phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-day cycles; or placebo (n = 67). Crossover to lenalidomide or higher dose was allowed after 16 weeks. More patients in the lenalidomide 10- and 5-mg groups achieved RBC-transfusion independence (TI) for ≥ 26 weeks (primary endpoint) versus placebo (56.1% and 42.6% vs 5.9%; both P < .001). Median duration of RBC-TI was not reached (median follow-up, 1.55 years), with 60% to 67% of responses ongoing in patients without progression to acute myeloid leukemia (AML). Cytogenetic response rates were 50.0% (10 mg) versus 25.0% (5 mg; P = .066). For the lenalidomide groups combined, 3-year overall survival and AML risk were 56.5% and 25.1%, respectively. RBC-TI for ≥ 8 weeks was associated with 47% and 42% reductions in the relative risks of death and AML progression or death, respectively (P = .021 and .048). The safety profile was consistent with previous reports. Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome. This trial was registered at www.clinicaltrials.gov as #NCT00179621.
科研通智能强力驱动
Strongly Powered by AbleSci AI